BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30326937)

  • 1. AFF3 upregulation mediates tamoxifen resistance in breast cancers.
    Shi Y; Zhao Y; Zhang Y; AiErken N; Shao N; Ye R; Lin Y; Wang S
    J Exp Clin Cancer Res; 2018 Oct; 37(1):254. PubMed ID: 30326937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
    Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.
    Mohseni M; Cidado J; Croessmann S; Cravero K; Cimino-Mathews A; Wong HY; Scharpf R; Zabransky DJ; Abukhdeir AM; Garay JP; Wang GM; Beaver JA; Cochran RL; Blair BG; Rosen DM; Erlanger B; Argani P; Hurley PJ; Lauring J; Park BH
    Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17606-11. PubMed ID: 25422431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
    Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
    Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
    BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
    Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH
    BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
    Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
    Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
    Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
    Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.
    Peng WX; Huang JG; Yang L; Gong AH; Mo YY
    Mol Cancer; 2017 Oct; 16(1):161. PubMed ID: 29041978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.
    Ma G; He J; Yu Y; Xu Y; Yu X; Martinez J; Lonard DM; Xu J
    Int J Biol Sci; 2015; 11(5):618-28. PubMed ID: 25892968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
    Ishii Y; Waxman S; Germain D
    Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
    Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
    Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.